Dermatology Billing Services in California

Medi-Cal covers medically necessary dermatologic services through the same county-organized managed care plan structure that covers other care: L.A. Care, Health Net, Molina Healthcare, CalOptima (Orange County), Inland Empire Health Plan, Partnership HealthPlan, Anthem Blue Cross's Medi-Cal product, and county-specific plans depending on the patient's residence. Coverage extends to skin cancer treatment (biopsy, excision, Mohs surgery for high-risk lesions in cosmetically sensitive sites), evaluation and management for inflammatory dermatoses, and limited biologic medications for severe psoriasis or hidradenitis through Drug Medi-Cal Rx. Cosmetic procedures are not covered. Each MCP has its own dermatology network, prior auth requirements (especially for Mohs in non-cosmetically-sensitive sites and biologics), and fee schedule. Medi-Cal fee-for-service runs on a six-month billing limit rather than a day count — a claim must be received within six months following the month in which services were rendered, or it is reduced or denied for late billing (Medi-Cal provider manual submission and timeliness instructions, verified 17 September 2026) — and each MCP sets its own contracted window and internal claim processing requirements on top of that. We build per-MCP workflows: L.A. Care's portal for Los Angeles County volume, CalOptima's prior auth requirements for biologic injectables, Health Net's documentation expectations for Mohs medical necessity.

Anthem Blue Cross and Blue Shield of California are the two dominant commercial dermatology payers in California, operating as separate licensee entities. Both have well-developed dermatology networks. For procedural dermatology — Mohs (17311, 17312), excision codes (11400-11646), biopsy (11102, 11104) — routine outpatient procedures typically don't require prior auth, but biologic medication infusions and select cosmetically-sensitive Mohs cases do. Anthem and Blue Shield each have separate medical policies on biologic dermatology drugs (Humira, Stelara, Cosentyx, Skyrizi, Dupixent, Tremfya), with step therapy requirements (typically failed methotrexate, cyclosporine, or phototherapy for psoriasis; failed topical/systemic for atopic dermatitis). Specialty pharmacy distribution affects billing — biologics are typically distributed through specialty pharmacies rather than buy-and-bill, which means the practice doesn't bill the J-code but instead bills the administration code (96401, 96372) at the office visit. Kaiser Permanente's closed-network model affects billing — non-Kaiser practices billing Kaiser members are out-of-network, with different reimbursement and patient liability.

Mohs micrographic surgery for skin cancer is one of the highest-revenue procedural services in California dermatology. 17311 (first stage, up to 5 tissue blocks) and 17312 (each additional stage) are reimbursed at substantially higher rates than non-Mohs excision because of the unique pathologist-surgeon combined workflow. California's high skin cancer incidence — driven by climate, lifestyle, and a large outdoor workforce — translates into high Mohs volume in coastal and inland practices alike. Medical necessity for Mohs (versus standard excision) is grounded in published Mohs Appropriate Use Criteria from the American Academy of Dermatology, focusing on tumor location (cosmetically sensitive sites — face, ears, hands, genitalia), histology (recurrent, aggressive, ill-defined), and patient factors. Anthem Blue Cross and Blue Shield require documentation referenced to AUC. Medi-Cal MCPs require prior auth for Mohs in non-AUC-typical scenarios. Repair codes (12001-13160 for layered closure, 14000-14302 for adjacent tissue transfer, 15000-15278 for skin grafts) are billed separately with appropriate place-of-service and modifier discipline.

11102 (tangential biopsy, single lesion) and 11104 (punch biopsy, single lesion) replaced the older 11100/11101 series in CPT 2019 — California payers have fully transitioned. Add-on codes 11103 and 11105 are billed for additional lesions during the same encounter. 17000 (destruction of first premalignant lesion, e.g., actinic keratosis) and 17003 (each additional lesion, 2-14) are heavily utilized in California given high actinic keratosis prevalence — Anthem Blue Cross and several Medi-Cal MCPs apply utilization edits when high counts are submitted. 17311 (Mohs first stage) and 17312 (Mohs each additional) require AUC documentation. Repair codes follow CPT lesion-size rules — California payers strictly apply the wound-size measurement requirement before closure type selection. Cosmetic procedure codes (15780 dermabrasion, 15786 chemical peel for cosmetic use, 17999 unlisted procedure for cosmetic) are non-covered for medical necessity-based billing. We document carefully when a procedure has both medical and cosmetic dimensions to avoid blanket cosmetic denials on medically necessary work.

California's Knox-Keene Act governs HMO operations including prior authorization timeframes (5 business days for routine, 72 hours for urgent), grievance procedures, and external review. For dermatology, the practical effect concentrates on biologic medications and Mohs in non-AUC-typical cases. Biologic prior auth pathways: Anthem Blue Cross (Carelon/MagellanRx for some product lines), Blue Shield (CVS Caremark or other PBMs depending on plan), Medi-Cal Drug Medi-Cal Rx (administered by Magellan Medicaid Administration). Step therapy is the norm for most biologics — documented failed trial of cheaper alternatives is required. We submit auth packets with the full clinical picture: diagnosis with PASI/EASI severity score where applicable, prior treatment timeline, contraindications to step-therapy alternatives. Adverse determinations can be peer-to-peer appealed and escalated to DMHC Independent Medical Review for Knox-Keene plans, which has historically overturned a meaningful share of dermatology biologic denials when the medical necessity narrative is strong.

California's prompt-pay clock changed on January 1, 2026, and a dermatology billing operation still calendaring in working days is letting statutory interest lapse. AB 3275 (Stats. 2024, Ch. 763) repealed and re-added Health & Safety Code 1371 and 1371.35, and AB 487 (Stats. 2025, Ch. 558) amended Insurance Code 10123.13. Under Section 1371(a)(1) a plan must reimburse a complete claim, or notify the claimant in writing that it is contested or denied, no later than 30 calendar days after receipt; Section 1371(a)(4) then accrues interest at 15 percent per annum from the first calendar day after that period, plus a fee of the greater of $15 or 10 percent of the accrued interest. Insurance Code 10123.13 puts CDI-regulated insurers on the identical standard. Two details decide how a derm practice calendars: the days are calendar days, not working days, and no separate paper-claim window survives in the code. A third decides which section to cite at all — Section 1371.35 now applies only to claims for a patient who was provided emergency services and care as defined in Section 1317.1, so it is not the section that governs an office-based dermatology claim, whatever an older billing manual says. Statutory text verified against leginfo.legislature.ca.gov on 17 September 2026. Default triggers DMHC enforcement for Knox-Keene plans and CDI enforcement for insurers. Stalled balances on Mohs claims, which can run $1,500-$3,000 per session including repair, accrue the most interest, and high-volume biopsy and destruction billing multiplies the per-claim fee. We age California claims against the 30-calendar-day statute and bill the interest line separately — a plan that pays the claim and omits accrued interest has not paid the claim in full.